AGL anticorps (C-Term)

N° du produit ABIN389030

L’anticorps Lapin Polyclonal anti-AGL a été validé pour WB et IF. Il convient pour détecter AGL dans des échantillons de Humain. Il y a 6+ publications disponibles.

Aperçu rapide pour AGL anticorps (C-Term) (ABIN389030)

Antigène: AGL (Amylo-alpha-1, 6-Glucosidase, 4-alpha-Glucanotransferase (AGL))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp AGL est non-conjugé

Application: Western Blotting (WB), Immunofluorescence (IF)

Clone: RB4978

Détail du produit anti-AGL anticorps

Épitope: AA 1479-1510, C-Term

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogène: This AGL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1479-1510 amino acids from the C-terminal region of human AGL.

Isotype: Ig Fraction

Information d'application

Indications d'application: IF: 1:10~50. IF: 1:10~50. WB: 1:1000. WB: 1:8000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Date de péremption: 6 months

Références pour anticorps anti-AGL (ABIN389030)

Guin, Ru, Agarwal, Ritterson Lew, Owens, Comi, Theodorescu: "Loss of glycogen debranching enzyme AGL drives bladder tumor growth via induction of hyaluronic acid synthesis." dans: Clinical cancer research : an official journal of the American Association for Cancer Research, (2015) (PubMed).

Liu, Zeng, Ma, Baba, Zheng, Liu, Wang: "Laforin-malin complex degrades polyglucosan bodies in concert with glycogen debranching enzyme and brain isoform glycogen phosphorylase." dans: Molecular neurobiology, Vol. 49, Issue 2, pp. 645-57, (2014) (PubMed).

Zhu, Shen, Zhu, Coorey, Nguyen, Barthelmes, Gillies: "Anti-retinal antibodies in patients with macular telangiectasia type 2." dans: Investigative ophthalmology & visual science, Vol. 54, Issue 8, pp. 5675-83, (2013) (PubMed).

DePaoli-Roach, Tagliabracci, Segvich, Meyer, Irimia, Roach: "Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin." dans: The Journal of biological chemistry, Vol. 285, Issue 33, pp. 25372-81, (2010) (PubMed).

Parker, Kong, Walsh, Salajegheh, Moghadaszadeh, Amato, Nazareno, Lin, Krastins, Sarracino, Beggs, Pinkus, Greenberg: "Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis." dans: Muscle & nerve, Vol. 39, Issue 6, pp. 739-53, (2009) (PubMed).

Cheng, Zhang, Gentry, Worby, Dixon, Saltiel: "A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease." dans: Genes & development, Vol. 21, Issue 19, pp. 2399-409, (2007) (PubMed).

Détails sur AGL

Antigène: AGL (Amylo-alpha-1, 6-Glucosidase, 4-alpha-Glucanotransferase (AGL))

Autre désignation: AGL

Sujet: AGL is a glycogen debrancher enzyme which is involved in glycogen degradation. This enzyme has two independent catalytic activities which occur at different sites on the protein: a 4-alpha-glucotransferase activity and a amylo-1,6-glucosidase activity. Mutations in the AGL gene are associated with glycogen storage disease although a wide range of enzymatic and clinical variability occurs which may be due to tissue-specific alternative splicing.

Poids moléculaire: 174764

ID gène: 178

NCBI Accession: NP_000019, NP_000633, NP_000634, NP_000635, NP_000636, NP_000637

UniProt: P35573

Pathways: Cellular Glucan Metabolic Process